Zobrazeno 1 - 10
of 53
pro vyhledávání: '"bernard FLOURIE"'
Autor:
Rémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, Xavier Roblin, Jean-Benoit Leluduec, Stéphane Paul, Thibaut Almeras, Karine Ruel, Anthony Buisson, Jacques Bienvenu, Cendrine Josson, Renaud Jasnowski, Stéphane Legastelois, Arnaud Foussat, Camille Meunier, Christophe Viret, Aurore Rozieres, Mathias Faure, Dominique Kaiserlian, Stéphane Nancey
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Background and aimsWe aimed to analyze circulating CD4+ T cell subsets and cytokines during the course of Crohn’s disease (CD).Methods and resultsCD4+ T cell subsets, ultrasensitive C-reactive protein (usCRP), and various serum cytokines (IL-6, IL-
Externí odkaz:
https://doaj.org/article/a33f3c4a5c4743d6a6197b9307a0eb6b
Autor:
Xavier Roblin, Pauline Veyrard, Laetitia Bastide, Anne E. Berger, Mathilde Barrau, Anne‐Sophie Paucelle, Louis Waeckel, Sany Kwiatek, Bernard Flourie, Stephane Nancey, Stéphane Paul
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 56(1)
The new subcutaneous (sc) formulation of the infliximab (IFX) biosimilar CT-P13 results in homogeneous serum trough concentrations of IFX at steady state. The present study aimed to investigate in Crohn's disease (CD) patients the intra-individual va
Autor:
Mathurin, Fumery, Laurent, Peyrin-Biroulet, Stephane, Nancey, Romain, Altwegg, Cyrielle, Gilletta, Pauline, Veyrard, Guillaume, Bouguen, Stephanie, Viennot, Florian, Poullenot, Jerome, Filippi, Anthony, Buisson, Anne, Bozon, Franck, Brazier, Lieven, Pouillon, Bernard, Flourie, Lucile, Boivineau, Laurent, Siproudhis, David, Laharie, Xavier, Roblin, Momar, Diouf, Xavier, Treton
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩
Journal of Crohn's and Colitis, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩
Journal of Crohn's and Colitis, Elsevier-Oxford University Press, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩
International audience; Introduction: The approved maintenance regimens for ustekinumab in Crohn's disease (CD) are 90 mg every 8 or 12 weeks. Some patients will partially respond to ustekinumab or will experience a secondary loss of response. It rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8b0b2a0fa0dc81a79e014e5c3f29d52a
https://doi.org/10.1093/ecco-jcc/jjaa177
https://doi.org/10.1093/ecco-jcc/jjaa177
Autor:
Florian Veyre, Gilles Boschetti, Camille Meunier, Charlotte Cuerq, Claire Gay, Anne-Laure Charlois, Remi Duclaux-Loras, Pauline Danion, Eddy Cotte, Vahan Kepenekian, Anne Mialon, Mathias Faure, Xavier Roblin, Bernard Flourie, Stéphane Nancey
Publikováno v:
Digestive Diseases and Sciences
Digestive Diseases and Sciences, Springer Verlag, 2021, Online ahead of print. ⟨10.1007/s10620-020-06751-z⟩
Digestive Diseases and Sciences, 2021, 66 (12), pp.4429-4435. ⟨10.1007/s10620-020-06751-z⟩
Digestive Diseases and Sciences, Springer Verlag, 2021, Online ahead of print. ⟨10.1007/s10620-020-06751-z⟩
Digestive Diseases and Sciences, 2021, 66 (12), pp.4429-4435. ⟨10.1007/s10620-020-06751-z⟩
International audience; BACKGROUND/AIMS: In Crohn's disease (CD) few data are available on the usefulness of monitoring fecal calprotectin (FC) in the early postoperative setting. We assessed prospectively the accuracy of FC measured 3 months after s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505679075910359a21cc7082d3abe188
https://www.hal.inserm.fr/inserm-03274438
https://www.hal.inserm.fr/inserm-03274438
Autor:
Quentin, Tournier, Stephane, Paul, Nicolas, Williet, Anne-Emmanuelle, Berger, Pauline, Veyrard, Gilles, Boschetti, Bertrand, Le Roy, Martin, Killian, Jean Marc, Phelip, Bernard, Flourie, Stephane, Nancey, Xavier, Roblin
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 53(11)
Anti-drug antibodies develop mostly during the induction therapy with anti-tumour necrosis factor (TNF) drugs and can be revealed by means of a drug-tolerant assay.To investigate whether the early detection of anti-drug antibodies during the inductio
Autor:
STEPHANE NANCEY, Francois MION, Nathalie Ganne-Carrié, ANTOINE CORTOT, Laurent Siproudhis, Bernard FLOURIE, ROBERT BENAMOUZIG, Isabelle Rosa, Jean-Ariel BRONSTEIN, Matthieu Allez, Frederic Gottrand, Guillaume Savoye, Gerard Thiefin, Xavier Roblin, Fabrice Carrat, Jean-Pierre Hugot, Bertrand Napoleon, Pierre DESREUMAUX, Laurent Peyrin-biroulet, Laurent Michaud, Christos CHRISTIDIS, Stéphane Nahon
Publikováno v:
Alimentary Pharmacology & Therapeutics (Suppl)
Alimentary Pharmacology & Therapeutics (Suppl), 2017, 45 (4), pp.533-541. ⟨10.1111/apt.13897⟩
Alimentary Pharmacology & Therapeutics (Suppl), 2017, 45 (4), pp.533-541. ⟨10.1111/apt.13897⟩
SummaryBackground Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer (CRC) in inflammatory bowel (IBD) disease is controversial. Aim To assess simultaneously the chemopreventive effect of aminosalicylates or thiopurines in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64e45bd089cd082dccb96205bea22ab
https://hal.science/hal-01897718/document
https://hal.science/hal-01897718/document
Autor:
STEPHANE NANCEY, Francois MION, Nathalie Ganne-Carrié, Dany GARGOT, ANTOINE CORTOT, Laurent Siproudhis, Bernard FLOURIE, ROBERT BENAMOUZIG, Tabassome SIMON, Frederic Gottrand, Guillaume Savoye, Gerard Thiefin, Antoine Pariente, Xavier Roblin, Fabrice Carrat, Harry Sokol, Jean-Pierre Hugot, Bertrand Napoleon, Pierre DESREUMAUX, Laurent Peyrin-biroulet, Laurent Michaud, Christos CHRISTIDIS
Publikováno v:
Gut
Gut, BMJ Publishing Group, 2013, 63, pp.1416-1423. ⟨10.1136/gutjnl-2013-305763⟩
Gut, BMJ Publishing Group, 2013, 63, pp.1416-1423. 〈10.1136/gutjnl-2013-305763〉
Gut, 2013, 63, pp.1416-1423. ⟨10.1136/gutjnl-2013-305763⟩
Gut, BMJ Publishing Group, 2013, 63, pp.1416-1423. ⟨10.1136/gutjnl-2013-305763⟩
Gut, BMJ Publishing Group, 2013, 63, pp.1416-1423. 〈10.1136/gutjnl-2013-305763〉
Gut, 2013, 63, pp.1416-1423. ⟨10.1136/gutjnl-2013-305763⟩
International audience; OBJECTIVE: To explore the risk of new or recurrent cancer among patients with IBD and previous cancer, exposed or not to immunosuppressants. DESIGN: Among the 17 047 patients of the CESAME prospective observational cohort who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b790f46bd221b15c8fa065d52eb1af1
https://hal.archives-ouvertes.fr/hal-00877944
https://hal.archives-ouvertes.fr/hal-00877944
Autor:
STEPHANE NANCEY, Francois MION, Nathalie Ganne-Carrié, Dany GARGOT, ANTOINE CORTOT, Laurent Siproudhis, Bernard FLOURIE, ROBERT BENAMOUZIG, Matthieu Allez, Tabassome SIMON, Frederic Gottrand, Guillaume Savoye, Gerard Thiefin, Fabrice Carrat, Harry Sokol, Jean-Pierre Hugot, Pierre DESREUMAUX, Laurent Peyrin-biroulet, Laurent Michaud, Christos CHRISTIDIS
Publikováno v:
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, Lippincott, Williams & Wilkins, 2012, 18 (11), pp.2063-2071. ⟨10.1002/ibd.22889⟩
Inflammatory Bowel Diseases, 2012, 18 (11), pp.2063-2071. ⟨10.1002/ibd.22889⟩
Inflammatory Bowel Diseases, Lippincott, Williams & Wilkins, 2012, 18 (11), pp.2063-2071. 〈10.1002/ibd.22889〉
Inflammatory Bowel Diseases, Lippincott, Williams & Wilkins, 2012, 18 (11), pp.2063-2071. ⟨10.1002/ibd.22889⟩
Inflammatory Bowel Diseases, 2012, 18 (11), pp.2063-2071. ⟨10.1002/ibd.22889⟩
Inflammatory Bowel Diseases, Lippincott, Williams & Wilkins, 2012, 18 (11), pp.2063-2071. 〈10.1002/ibd.22889〉
International audience; BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89e7dbe8bae048ba3be803a7c4272dc
https://hal.archives-ouvertes.fr/hal-00683356
https://hal.archives-ouvertes.fr/hal-00683356
Autor:
STEPHANE NANCEY, Francois MION, Nathalie Ganne-Carrié, Dany GARGOT, ANTOINE CORTOT, Laurent Siproudhis, Bernard FLOURIE, ROBERT BENAMOUZIG, Kiarash Khosrotehrani, Frederic Gottrand, Guillaume Savoye, Gerard Thiefin, Fabrice Carrat, Jean-Pierre Hugot, Pierre DESREUMAUX, Laurent Peyrin-biroulet, Laurent Michaud, Christos CHRISTIDIS, Stéphane Nahon
Publikováno v:
Gastroenterology
Gastroenterology, WB Saunders, 2011, 141 (5), pp.1621-28.e1-5. ⟨10.1053/j.gastro.2011.06.050⟩
Gastroenterology, 2011, 141 (5), pp.1621-28.e1-5. ⟨10.1053/j.gastro.2011.06.050⟩
Gastroenterology, WB Saunders, 2011, 141 (5), pp.1621-28.e1-5. 〈10.1053/j.gastro.2011.06.050〉
Gastroenterology, WB Saunders, 2011, 141 (5), pp.1621-28.e1-5. ⟨10.1053/j.gastro.2011.06.050⟩
Gastroenterology, 2011, 141 (5), pp.1621-28.e1-5. ⟨10.1053/j.gastro.2011.06.050⟩
Gastroenterology, WB Saunders, 2011, 141 (5), pp.1621-28.e1-5. 〈10.1053/j.gastro.2011.06.050〉
International audience; BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) who have been exposed to thiopurines might have an increased risk of skin cancer. We assessed this risk among patients in France. METHODS: We performed a prospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a17eb8aa76430acd624ae256c5c3f82
https://hal.archives-ouvertes.fr/hal-00631539
https://hal.archives-ouvertes.fr/hal-00631539
Autor:
STEPHANE NANCEY, Francois MION, Nathalie Ganne-Carrié, Dany GARGOT, ANTOINE CORTOT, Laurent Siproudhis, Bernard FLOURIE, ROBERT BENAMOUZIG, Tabassome SIMON, Frederic Gottrand, Guillaume Savoye, Gerard Thiefin, Fabrice Carrat, Jean-Pierre Hugot, Pierre DESREUMAUX, Laurent Peyrin-biroulet, Laurent Michaud, Christos CHRISTIDIS, Olivier Hermine
Publikováno v:
The Lancet
The Lancet, Elsevier, 2009, 374 (9701), pp.1617-25. 〈10.1016/S0140-6736(09)61302-7〉
The Lancet, Elsevier, 2009, 374 (9701), pp.1617-25. ⟨10.1016/S0140-6736(09)61302-7⟩
The Lancet, 2009, 374 (9701), pp.1617-25. ⟨10.1016/S0140-6736(09)61302-7⟩
The Lancet, Elsevier, 2009, 374 (9701), pp.1617-25. 〈10.1016/S0140-6736(09)61302-7〉
The Lancet, Elsevier, 2009, 374 (9701), pp.1617-25. ⟨10.1016/S0140-6736(09)61302-7⟩
The Lancet, 2009, 374 (9701), pp.1617-25. ⟨10.1016/S0140-6736(09)61302-7⟩
International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5099a913a752bf9f0fcafbc176727015
https://hal.archives-ouvertes.fr/hal-00466312
https://hal.archives-ouvertes.fr/hal-00466312